Advertisement

The Charlson Comorbidity Index: problems with use in epidemiological research

  • Allison Drosdowsky
    Correspondence
    Corresponding author. Peter MacCallum Cancer Centre, Department of Health Services Research, Locked Bag 1, A'Beckett St, Melbourne, Victoria, Australia. Tel.: +61-3-8559-7842; fax: +61-3-8559-5909.
    Affiliations
    Department of Health Services Research, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia
    Search for articles by this author
  • Karla Gough
    Affiliations
    Department of Health Services Research, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia

    Department of Nursing, Faculty of Medicine, Dentistry, and Health Sciences, The University of Melbourne, Parkville, Victoria 3010, Australia
    Search for articles by this author

      Abstract

      The Charlson Comorbidity Index (CCI) is a highly cited and well established tool for measuring comorbidity in clinical research, but there are problems with its use in practice. Like most comorbidity summary measures, the CCI was developed to adjust for prognostic comorbidities in statistical models, particularly those exploring associations between a risk of death or survival time and other patient-related and disease-related factors. Despite this, the CCI is often used in cancer research to measure all comorbidity, or as a multimorbidity measure, and CCI scores are often used to assess the prognostic importance of multiple health conditions. In the latter case, it is not at all surprising that researchers report a significant association between CCI scores and a risk of death or survival times because CCI scores provide a summary of the presence or absence of a set of prognostic comorbidities. Advances in multimorbidity research require specific attention to the methods used to develop relevant indices. Published literature on the association between the comorbidity and risk of death or survival time should be interpreted with caution, especially if the CCI was used to provide a measure of comorbidities.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Epidemiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Feinstein A.R.
        The pre-therapeutic classification of co-morbidity in chronic disease.
        J Chronic Dis. 1970; 23: 455-468
        • Sarfati D.
        • Koczwara B.
        • Jackson C.
        The impact of comorbidity on cancer and its treatment.
        CA Cancer J Clin. 2016; 66: 337-350
        • van den Akker M.
        • Buntinx F.
        • Knottnerus J.A.
        Comorbidity or multimorbidity: what's in a name? A review of literature.
        Eur J Gen Pract. 1996; 2: 65-70
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • MacKenzie C.R.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Quan H.
        • Li B.
        • Couris C.M.
        • Fushimi K.
        • Graham P.
        • Hider P.
        • et al.
        Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.
        Am J Epidemiol. 2011; 173: 676-682
        • Singh B.
        • Bhaya M.
        • Stern J.
        • Roland J.T.
        • Zimbler M.
        • Rosenfeld R.M.
        • et al.
        Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study.
        Laryngoscope. 1997; 107: 1469-1475
        • Birim Ö.
        • Maat A.
        • Kappetein A.P.
        • Van Meerbeeck J.
        • Damhuis R.
        • Bogers A.
        Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer.
        Eur J Cardiothorac Surg. 2003; 23: 30-34
        • Schmolders J.
        • Friedrich M.J.
        • Michel R.
        • Strauss A.C.
        • Wimmer M.D.
        • Randau T.M.
        • et al.
        Validation of the Charlson comorbidity index in patients undergoing revision total hip arthroplasty.
        Int Orthop. 2015; 39: 1771-1777
        • Radovanovic D.
        • Seifert B.
        • Urban P.
        • Eberli F.R.
        • Rickli H.
        • Bertel O.
        • et al.
        • AMIS Plus Investigators
        Validity of Charlson Comorbidity Index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002–2012.
        Heart. 2014; 100: 288-294
        • Quan H.
        • Sundararajan V.
        • Halfon P.
        • Fong A.
        • Burnand B.
        • Luthi J.-C.
        • et al.
        Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.
        Med Care. 2005; 43: 1130-1139
        • Mehta H.B.
        • Mehta V.
        • Girman C.J.
        • Adhikari D.
        • Johnson M.L.
        Regression coefficient–based scoring system should be used to assign weights to the risk index.
        J Clin Epidemiol. 2016; 79: 22-28
        • Harrell F.
        Regression coefficients and scoring rules.
        J Clin Epidemiol. 1996; 49: 819
        • Knottnerus J.A.
        • Tugwell P.
        • Wells G.
        Editorial comment: ratios should be multiplied, not added.
        J Clin Epidemiol. 2016; 79: 30
        • Zavascki A.P.
        • Fuchs S.C.
        The need for reappraisal of AIDS score weight of Charlson comorbidity index.
        J Clin Epidemiol. 2007; 60: 867-868
        • Søgaard M.
        • Thomsen R.W.
        • Bossen K.S.
        • Sorensen H.
        • Norgaard M.
        The impact of comorbidity on cancer survival: a review.
        Clin Epidemiol. 2013; 5: 3-29
        • Roxburgh C.
        • McDonald A.
        • Salmond J.
        • Oien K.
        • Anderson J.
        • McKee R.
        • et al.
        Adjuvant chemotherapy for resected colon cancer: comparison of the prognostic value of tumour and patient related factors.
        Int J Colorectal Dis. 2011; 26: 483-492
        • Piccirillo J.F.
        • Tierney R.M.
        • Costas I.
        • Grove L.
        • Spitznagel Jr., E.L.
        Prognostic importance of comorbidity in a hospital-based cancer registry.
        JAMA. 2004; 291: 2441-2447
        • Jiao Y.-S.
        • Gong T.-T.
        • Wang Y.-L.
        • Wu Q.-J.
        Comorbidity and survival among women with ovarian cancer: evidence from prospective studies.
        Sci Rep. 2015; 5: 11720
        • Bøje C.R.
        Impact of comorbidity on treatment outcome in head and neck squamous cell carcinoma–a systematic review.
        Radiother Oncol. 2014; 110: 81-90
        • Sullivan M.K.
        • Rankin A.J.
        • Jani B.D.
        • Mair F.S.
        • Mark P.B.
        Associations between multimorbidity and adverse clinical outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.
        BMJ Open. 2020; 10: e038401
        • Hirlekar G.
        • Jonsson M.
        • Karlsson T.
        • Hollenberg J.
        • Albertsson P.
        • Herlitz J.
        Comorbidity and survival in out-of-hospital cardiac arrest.
        Resuscitation. 2018; 133: 118-123
        • Tabarés-Seisdedos R.
        • Dumont N.
        • Baudot A.
        • Valderas J.M.
        • Climent J.
        • Valencia A.
        • et al.
        No paradox, no progress: inverse cancer comorbidity in people with other complex diseases.
        Lancet Oncol. 2011; 12: 604-608
        • Braithwaite D.
        • Tammemagi C.M.
        • Moore D.H.
        • Ozanne E.M.
        • Hiatt R.A.
        • Belkora J.
        • et al.
        Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients.
        Int J Cancer. 2009; 124: 1213-1219
        • Hatlen P.
        • Grønberg B.H.
        • Langhammer A.
        • Carlsen S.M.
        • Amundsen T.
        Prolonged survival in patients with lung cancer with diabetes mellitus.
        J Thorac Oncol. 2011; 6: 1810-1817
        • Yancik R.
        • Wesley M.N.
        • Ries L.A.
        • Havlik R.J.
        • Edwards B.K.
        • Yates J.W.
        Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older.
        JAMA. 2001; 285: 885-892
        • Valderas J.M.
        • Starfield B.
        • Sibbald B.
        • Salisbury C.
        • Roland M.
        Defining comorbidity: implications for understanding health and health services.
        Ann Fam Med. 2009; 7: 357-363
        • Stirland L.E.
        • González-Saavedra L.
        • Mullin D.S.
        • Ritchie C.W.
        • Muniz-Terrera G.
        • Russ T.C.
        Measuring multimorbidity beyond counting diseases: systematic review of community and population studies and guide to index choice.
        BMJ. 2020; 368: m160